



PATENT  
Docket No.: GMR-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1645

Examiner: Not Yet Assigned

Serial No.: 09/643,128

Filed: August 21, 2000

In re Application of: Jifan Hu et al.

For: GENE INACTIVATION BY TARGETED DNA METHYLATION

RECEIVED  
APR 23 2003  
TECH CENTER 1600/2900

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to Director of Patents, Washington, D.C. 20231 on April 18, 2003. Signed Krista Thompson  
Krista Thompson

**INFORMATION DISCLOSURE STATEMENT**

Director of Patents  
Washington, D.C. 20231

Dear Sir:

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached, may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

This Information Disclosure Statement under 37 CFR §§1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

## I

This statement is filed pursuant to:

( X ) 37 C.F.R. §1.97(b).

This information disclosure statement is filed either (1) within three months of the filing date of the national applications; (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or (3) before the mailing date of a first office action on the merits, whichever event occurs last.

Accordingly, this information disclosure statement requires no fee and no certification.

( ) 37 C.F.R. §1.97(c).

This information disclosure statement is filed after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of either (1) a final action under 37 C.F.R. §1.113 or (2) a notice of allowance under 37 C.F.R. §1.311.

Accordingly, this information disclosure statement requires either the fee specified in 37 C.F.R. § 1.17 (p) or a certification according to 37 C.F.R. §1.97(e).

( ) 37 C.F.R. §1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. §1.97(c).

Accordingly, this information disclosure statement requires the fee specified in 37 C.F.R. §1.17(p), \$180.00, for submission of an information disclosure statement under 37 C.F.R. §1.97(d), and a statement according to 37 C.F.R. §1.97(e).

37 C.F.R. §1.97(e).

( ) (1) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

( ) (2) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c), more than three months prior to the filing of the statement.

Accordingly, this information disclosure statement requires the fee specified in 37 C.F.R. §1.17(p), \$180.00, for submission of an information disclosure statement under 37 C.F.R. §1.97(e).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. §1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II


( X ) No fee is due.

( ) The fee specified in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under 37 C.F.R. §1.97(c), 37 C.F.R. § 1.97(d), or 37 C.F.R. §1.97(e) is enclosed, \$180.00.

In the event any fee is required for filing the above-noted document, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing attached document timely, the Assistant Commissioner is hereby authorized to charge the fee to our Deposit Account No. 50-0612. A duplicate of this page is enclosed.


Respectfully submitted,  
SIERRA PATENT GROUP, LTD.

Dated: *April 18, 2003*



Barbara J. Luther  
Reg. No.: 33,954

Sierra Patent Group, Ltd.  
P.O. Box 6149  
Stateline, NV 89449  
(775) 586-9500  
(775) 586-9550 Fax



Form PTO 1449 (Rev. 2-32)				U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. GMR-001		Serial No. 09/645,428	
Information Disclosure Statement by Applicant						Applicant: Jifan Hu et al.			
(Use several sheets if necessary)						Filed: August 21, 2000 Group: 1645			
U.S. Patent Documents									
Init.		Document No.	Date	Name	Class	Subclass	Filing Date		
Foreign Documents									
Translation									
Init.		Document No.	Date	Country	Class	Subclass	Yes	No	
	24	WO 93/24640 A2 & A3	12/09/1993	PCT (US)	C12N	15/85		X	
	25	WO 96/18372 A2 & A3	06/20/1996	PCT (US)	C07J (A3 listing)	41/00		X	
	26	WO 97/44346	11/27/1997	PCT (Canada)	C07H	21/00		X	
Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)									
	27	A. Weissbach et al., "The Effect of flanking sequences on the <i>DE NOVO</i> Methylation of C-G pairs by the Human DNA Methylase", <u>Biochemistry and Biology of DNA Methylation</u> , pp. 79-94, Alan R. Liss, Inc. 1985 (no month). ✓							
	28	H. Gao et al., "Stabilization of double-stranded oligonucleotides using backbone-linked disulfide bridges", <u>Nucleic Acids Research</u> , Vol. 23, No. 2, pp. 285-292, January 1995. ✓							
	29	S. Pradhan et al., "CG and CNG methyltransferases in plants", <u>Gene</u> , Vol. 157, pp. 289-291, 1995 (no month). ✓							
	30	J. Hu et al., "Differential Biallelic Activation of Three Insulin-Like Growth Factor II Promoters in the Mouse Central Nervous System", <u>Molecular Endocrinology</u> , Vol. 9, No. 5, pp. 628-636, May 1995. ✓							
	31	S. Saitoh et al., "Minimal definition of the imprinting center and fixation of a chromosome 15q11-q13 epigenotype by imprinting mutations", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 7811-7815, July 1996 ✓ *							
	32	J. Hu et al., "Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet", <u>Oncogene</u> , Vol. 15, pp. 2795-2801, December 1997. ✓							
	33	J. Hu et al., "Tissue-Specific Imprinting of the Mouse Insulin-Like Growth Factor II Receptor Gene Correlates with Differential Allele-Specific DNA Methylation", <u>Molecular Endocrinology</u> , Vol. 12, No. 2, pp. 220-232, February 1998. ✓							
	34	Y. Birger et al., "The imprinting box of the mouse <i>Igf2r</i> gene", <u>Nature</u> , Vol. 397, pp. 84-88, January 7, 1999 ✓							
	35	M. Frevel et al., "A potential imprint control element identification of a conserved 42 bp sequence upstream of H19", <u>TIG</u> , Vol. 15, No. 6, pp. 216-218, June 1999. ✓							
	36	T. Vu et al., "Symmetric and Asymmetric DNA Methylation in the Human IGF2-H19 Imprinted Region", <u>Genomics</u> , Vol. 64, pp. 132-143, 2000 (no month).							
Examiner						Date Considered			
Examiner: Initial if citation considered, whether or not citation is in conference with MPEP 609; Draw line through citation if not conformance and not considered. Include a copy of this form with the next communication to applicant.									

